Danaher Corporation (DHR) is scheduled to release second-quarter 2024 results on Jul 23, before market open.The company’s earnings surpassed the Zacks Consensus Estimate in each of the trailing four quarters, the average surprise being 8.6%. In the last reported quarter, its earnings of $1.92 per share beat the consensus estimate of $1.72 by 11.6%.Let’s see how things have shaped up for Danaher this earnings season.Key Factors and Estimates for Q2Strength in the molecular diagnostics business, driven by inc ...

DH Diagnostics LLC Centers aim to accelerate drug development by speeding and streamlining development and commercialization of companion diagnostics.Clinical Laboratory Improvement Amendments (CLIA) and College of American Pathologists (CAP)-certified laboratories will bring technologies and assays from multiple Danaher subsidiaries together under a single roof.WASHINGTON, July 17, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) ("Danaher"), a global science and technology innovator, announced the lau ...

Danaher (DHR) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years.Individual investors o ...

Investors interested in Conglomerates stocks should always be looking to find the best-performing companies in the group. Has Danaher (DHR) been one of those stocks this year? Let's take a closer look at the stock's year-to-date performance to find out.Danaher is one of 24 individual stocks in the Conglomerates sector. Collectively, these companies sit at #1 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Ra ...

WASHINGTON, July 16, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) ("Danaher" or the "Company"), the global life sciences and diagnostics innovator, today published its 2024 Sustainability Report which conveys the depth and scope of Danaher's sustainability program and highlights important milestones the Company achieved during the past year."At the heart of everything we do at Danaher is our commitment to continuous improvement, and our sustainability program exemplifies this commitment," said Raine ...

Predictive tools will seek to reduce leading cause of failure rates in clinical trials of oncology drugs. Integrated AI and microscopy expected to lead to better understanding of tumor structures and treatment strategies.New technology will work to capture and analyze the highly heterogeneous tumor microenvironment.WASHINGTON, July 11, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR), a global science and technology innovator, today launched a research collaboration with Stanford University's Department ...

Ideally Suited for Satellite and Independent Labs, the new DxC 500i Analyzer Offers Flexibility, Scalability and Data Commutability with Extensive Chemistry and Immunoassay Assay MenuThe New DxC 500i Analyzer Incorporates Recently Introduced DxC 500 AU Chemistry Analyzer Technology with Six Sigma PerformanceBREA, Calif., July 9, 2024 /PRNewswire/ -- Beckman Coulter Diagnostics, a clinical diagnostics leader, today introduces the new DxC 500i Clinical Analyzer*, an integrated clinical chemistry and immunoass ...

WASHINGTON, June 24, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the second quarter 2024 on Tuesday, July 23, 2024 beginning at 8:00 a.m. ET and lasting approximately one hour. During the call, the company will discuss its financial performance, as well as future expectations.The call and an accompanying slide presentation will be webcast on the "Investors" section of Danaher's website, www.danaher.com, under the subheading " ...

WASHINGTON, June 19, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) ("Danaher" or the "Company"), a leading global life sciences and diagnostics innovator, today announced that Julie Sawyer Montgomery will succeed Joakim Weidemanis as Executive Vice President, Diagnostics effective as of July 1, 2024. Mr. Weidemanis will support the transition over the next three months and will retire from Danaher on September 30, 2024 after 13 years of service.  Ms. Sawyer Montgomery, currently Vice President and Gr ...

Danaher Corporation (DHR) is posed to gain from strength in the Life Sciences segment and accretive acquisitions.However, softness in the Biotechnology segment raises concerns for the company. Decreased demand in the bioprocessing business has been weighing on the performance of the segment. Given the company’s international exposure, forex woes are weighing on its top line.What’s Aiding DHR?Business Strength: Stable demand in the academic and applied markets and strong momentum in the genomics consumables ...